The Community Guide

- gsearch

Search Results

Narrow Results:

2023 1
2019 2
2015 1
2013 2
2011 1
2010 1
1979 1

Journal Article 7
Journal Issue 1

Statistics 1

1 - 9 of 9 Results

Refine Results

Refine Results:

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

CITE Title : Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination Personal Author(s) : Shing, Jaimie Z.;Hull, Pamela C.;Zhu, Yuwei;Gargano, Julia W.;Markowitz, Lauri E.;Cleveland, Angela A.;Pemmaraju, Manideepthi;Park, Ina U.;Whitney, Erin;Mitchel, Edward F.;Griffin, Marie R.; Published Date : April 10 2019 Source : Papillomavirus Res. 2019; 7:141-149 URL : https://stacks.cdc.gov/view/cdc/78193 Shing, Jaimie Z. et al. (2019). Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination. 7 Shing, Jaimie Z. et al. "Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination" 7 (2019) Shing, Jaimie Z. et al. "Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination" vol. 7, 2019 Export RIS Citation Information.

:

Shing, Jaimie Z. ;

Hull, Pamela C.

April 10 2019 | Papillomavirus Res. 2019; 7:141-149

:

IntroductionEvidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated ...
Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States

CITE Title : Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States Personal Author(s) : Clay, Patrick A.;Thompson, Trevor D.;Markowitz, Lauri E.;Ekwueme, Donatus U.;Saraiya, Mona;Chesson, Harrell W.; Published Date : 3 31 2023;3-31-; Source : Vaccine. 41(14):2376-2381 URL : https://stacks.cdc.gov/view/cdc/128671 Clay, Patrick A. et al. (2023). Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States. 41(14). Clay, Patrick A. et al. "Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States" 41, no. 14 (2023) Clay, Patrick A. et al. "Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States" vol. 41, no. 14, 2023 Export RIS Citation Information.

:

Clay, Patrick A. ;

Thompson, Trevor D.

3 31 2023 | Vaccine. 41(14):2376-2381

:

The annual direct medical cost attributable to human papillomavirus (HPV) in the United States over the period 2004-2007 was estimated at $9.36 billio...
Population Impact of HPV Vaccines: Summary of Early Evidence

CITE Title : Population Impact of HPV Vaccines: Summary of Early Evidence Personal Author(s) : Hariri, Susan;Markowitz, Lauri E.;Dunne, Eileen F.;Unger, Elizabeth R.; Published Date : Dec 2013 Source : J Adolesc Health. 53(6):679-682 URL : https://stacks.cdc.gov/view/cdc/93863 Hariri, Susan et al. (2013). Population Impact of HPV Vaccines: Summary of Early Evidence. 53(6). Hariri, Susan et al. "Population Impact of HPV Vaccines: Summary of Early Evidence" 53, no. 6 (2013) Hariri, Susan et al. "Population Impact of HPV Vaccines: Summary of Early Evidence" vol. 53, no. 6, 2013 Export RIS Citation Information.

:

Hariri, Susan ;

Markowitz, Lauri E.

Dec 2013 | J Adolesc Health. 53(6):679-682

:

Human papillomavirus (HPV) vaccines are available in the United States and around the world to prevent HPV-associated diseases including cervical canc...
Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States

CITE Title : Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States Personal Author(s) : Chesson, Harrell W.;Ekwueme, Donatus U.;Saraiya, Mona;Dunne, Eileen F.;Markowitz, Lauri E.; Published Date : June 29 2013 Source : Vaccine. 31(37):3899-3905 URL : https://stacks.cdc.gov/view/cdc/81248 Chesson, Harrell W. et al. (2013). Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. 31(37). Chesson, Harrell W. et al. "Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States" 31, no. 37 (2013) Chesson, Harrell W. et al. "Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States" vol. 31, no. 37, 2013 Export RIS Citation Information.

:

Chesson, Harrell W. ;

Ekwueme, Donatus U.

June 29 2013 | Vaccine. 31(37):3899-3905

:

Background:The objective of this study was to estimate the number of years after onset of a quadrivalent HPV vaccination program before notable reduct...
Sexually Transmitted Diseases Treatment Guidelines, 2015

CITE Title : Sexually Transmitted Diseases Treatment Guidelines, 2015 Personal Author(s) : Workowski, Kimberly A.;Bolan, Gail A.; Published Date : 6 05 2015;6-05-; Source : MMWR Recomm Rep. 64(RR-03):1-137 URL : https://stacks.cdc.gov/view/cdc/53167 Workowski, Kimberly A. and Bolan, Gail A. (2015). Sexually Transmitted Diseases Treatment Guidelines, 2015. 64 Workowski, Kimberly A. and Bolan, Gail A. "Sexually Transmitted Diseases Treatment Guidelines, 2015" 64 (2015) Workowski, Kimberly A. and Bolan, Gail A. "Sexually Transmitted Diseases Treatment Guidelines, 2015" vol. 64, 2015 Export RIS Citation Information.

:

Workowski, Kimberly A. ;

Bolan, Gail A.

6 05 2015 | MMWR Recomm Rep. 64(RR-03):1-137

:

These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation ...
Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics—Sexually Transmitted Disease Surveillance Network, United States, 2010–2016

CITE Title : Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics—Sexually Transmitted Disease Surveillance Network, United States, 2010–2016 Personal Author(s) : Mann, Laura M.;Llata, Eloisa;Flagg, Elaine W.;Hong, Jaeyoung;Asbel, Lenore;Carlos-Henderson, Juli;Kerani, Roxanne P.;Kohn, Robert;Pathela, Preeti;Schumacher, Christina;Torrone, Elizabeth A.; Published Date : 4 16 2019;4-16-; Source : J Infect Dis. 219(9):1389-1397 URL : https://stacks.cdc.gov/view/cdc/83574 Mann, Laura M. et al. (2019). Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics—Sexually Transmitted Disease Surveillance Network, United States, 2010–2016. 219(9). Mann, Laura M. et al. "Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics—Sexually Transmitted Disease Surveillance Network, United States, 2010–2016" 219, no. 9 (2019) Mann, Laura M. et al. "Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics—Sexually Transmitted Disease Surveillance Network, United States, 2010–2016" vol. 219, no. 9, 2019 Export RIS Citation Information.

:

Mann, Laura M. ;

Llata, Eloisa

4 16 2019 | J Infect Dis. 219(9):1389-1397

:

Background.Approximately 90% of genital warts are caused by human papillomavirus (HPV) types 6 and 11. In the United States, HPV vaccination has been ...
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)

CITE Title : FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) Corporate Authors(s) : United States. Advisory Committee on Immunization Practices.;Centers for Disease Control and Prevention (U.S.); Published Date : May 28, 2010 Pages in Document : 3 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR. Morbidity and mortality weekly report. 2010; 59(20):630-2. URL : https://stacks.cdc.gov/view/cdc/7334 Journal Title : Morbidity and Mortality Weekly Report (MMWR) United States. Advisory Committee on Immunization Practices. (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). 59(20). United States. Advisory Committee on Immunization Practices. "FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)" 59, no. 20 (2010) United States. Advisory Committee on Immunization Practices. "FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)" vol. 59, no. 20, 2010 Export RIS Citation Information.

:

United States. Advisory Committee on Immunization Practices. ...

May 28, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the liter...

:

superseded
Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011

CITE Title : Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011 Corporate Authors(s) : United States. Advisory Committee on Immunization Practices Published Date : December 23, 2011 Pages in Document : 4 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR. Morbidity and mortality weekly report. 2011; 60(50):1705-8. URL : https://stacks.cdc.gov/view/cdc/7470 Journal Title : Morbidity and Mortality Weekly Report (MMWR) United States. Advisory Committee on Immunization Practices (2011). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. 60(50). United States. Advisory Committee on Immunization Practices "Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011" 60, no. 50 (2011) United States. Advisory Committee on Immunization Practices "Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011" vol. 60, no. 50, 2011 Export RIS Citation Information.

:

United States. Advisory Committee on Immunization Practices

December 23, 2011 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccin...

:

current
Morbidity and Mortality Weekly Report, Vol. 28, No. 6, February 16, 1979

CITE Title : Morbidity and Mortality Weekly Report, Vol. 28, No. 6, February 16, 1979 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : February 16, 1979 Pages in Document : [61]-72 p. Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR: Morbidity and Mortality Weekly Report 1979; v. 28, no. 6 URL : https://stacks.cdc.gov/view/cdc/1499 Centers for Disease Control and Prevention (U.S.) (1979). Morbidity and Mortality Weekly Report, Vol. 28, No. 6, February 16, 1979. 28(6). Centers for Disease Control and Prevention (U.S.) "Morbidity and Mortality Weekly Report, Vol. 28, No. 6, February 16, 1979" 28, no. 6 (1979) Centers for Disease Control and Prevention (U.S.) "Morbidity and Mortality Weekly Report, Vol. 28, No. 6, February 16, 1979" vol. 28, no. 6, 1979 Export RIS Citation Information.

:

Centers for Disease Control and Prevention (U.S.)

February 16, 1979 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

No Description